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Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the
first-line treatment for patients with EGFR mutant non-small-cell lung cancer
(NSCLC). However, most patients become resistant to these drugs, so their disease
progresses. Osimertinib, a third-generation EGFR-TKI that can inhibit the kinase
even when the common resistance-conferring Thr790Met (T790M) mutation is pre-
sent, is a promising therapeutic option for patients whose disease has progressed
after first-line EGFR-TKI treatment. AURA3 was a randomized (2:1), open-label,
phase III study comparing the efficacy of osimertinib (80 mg/d) with platinum-based
therapy plus pemetrexed (500 mg/m2) in 419 patients with advanced NSCLC with
the EGFR T790M mutation in whom disease had progressed after first-line EGFR-
TKI treatment. This subanalysis evaluated the safety and efficacy of osimertinib
specifically in 63 Japanese patients enrolled in AURA3. The primary end-point was
progression-free survival (PFS) based on investigator assessment. Improvement in
PFS was clinically meaningful in the osimertinib group (n = 41) vs the platinum-
pemetrexed group (n = 22; hazard ratio 0.27; 95% confidence interval, 0.13-0.56).
The median PFS was 12.5 and 4.3 months in the osimertinib and platinum-peme-
trexed groups, respectively. Grade ≥3 adverse events determined to be related to
treatment occurred in 5 patients (12.2%) treated with osimertinib and 12 patients
Abbreviations: AE, adverse event; CI, confidence interval; CNS, central nervous system; DCR, disease control rate; EGFR, epidermal growth factor receptor; ILD, interstitial lung disease;
NSCLC, non-small-cell lung cancer; ORR, objective response rate; PFS, progression-free survival; SAE, serious adverse event; T790M, EGFR Thr790Met mutation; TKI, tyrosine kinase
inhibitor.
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(54.5%) treated with platinum-pemetrexed. The safety and efficacy results in this
subanalysis are consistent with the results of the overall AURA3 study, and support
the use of osimertinib in Japanese patients with EGFR T790M mutation-positive
NSCLC whose disease has progressed following first-line EGFR-TKI treatment. (Clin-
icalTrials.gov trial registration no. NCT02151981.)
K E YWORD S
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1 | INTRODUCTION
Epidermal growth factor receptor TKIs are established as the first
line of treatment of patients with EGFR-mutated NSCLC.1 However,
resistance nearly always develops. Despite good response rates with
first-line EGFR-TKIs, most patients experience disease progression
within 8-14 months of treatment.1-3 A point mutation in the EGFR
gene leading to T790M is found in approximately 50%-60% of
EGFR-TKI-treated patients at the time of disease progression.4-7 This
mutation is believed to render the receptor refractory to inhibition
by reversible first-generation EGFR TKIs through effects on both
steric hindrance8 and increased ATP affinity.9 Although afatinib, an
irreversible second-generation EGFR TKI, overcame T790M activity
preclinically,10 it failed to overcome T790M-mediated resistance in
patients.11,12
Two studies of Japanese individuals found that the prevalence of
the EGFR T790M mutation was 50% and 64% in tumors with
acquired resistance to EGFR-TKIs.13,14 A previous study showed a
poor response to platinum-based doublet chemotherapy with or
without bevacizumab in Japanese NSCLC patients with de novo and
acquired EGFR T790M mutations, with overall response rates of
25.0% and 22.2% and median survival times of 29.1 and
15.3 months, respectively.15 After failure with first-line EGFR-TKI
treatment in Japanese patients with EGFR mutation-positive
advanced NSCLC, responses to platinum-based chemotherapy were
poor, as shown by an ORR and median survival time of 25.4% and
28.9 months, respectively.16 A phase II study of NSCLC patients,
including those with EGFR mutations, who experienced disease pro-
gression after erlotinib and/or gefitinib treatment also showed a
poor response, with an ORR and median PFS of 8.2% and
4.4 months, respectively, after treatment with the irreversible ErbB
family blocker, afatinib.12 In the same study, the best response in 2
patients with acquired EGFR T790M mutations was stable disease.
Osimertinib is an oral, irreversible, CNS-penetrant EGFR-TKI with
high selectivity for mutated EGFR, including EGFR with the T790M
mutation.17,18 A phase I study of osimertinib found an overall ORR
of 51% in patients who had progressed following prior treatment
with EGFR-TKI inhibitors. The response rate was 61% in evaluable
patients with confirmed EGFR T790M, and 21% in those without
detectable EGFR T790M.19 The safety and efficacy of osimertinib
80 mg once daily were studied in a phase II, single-arm study in
patients previously treated with an EGFR-TKI. In the analysis of data
from a phase II study in 199 patients, a complete objective response
was obtained in 3% of patients, and partial responses in 67%, with
manageable AEs.20
AURA3 is an international, randomized (2:1), open-label, phase
III clinical trial to compare the efficacy of osimertinib with that of
platinum-based therapy plus pemetrexed.21 The trial enrolled 419
EGFR T790M mutation-positive patients with advanced NSCLC
who had disease progression following first-line EGFR-TKI therapy.
Approximately two-thirds of the patients were Asian. Compared
with platinum therapy plus pemetrexed, median PFS was signifi-
cantly increased with osimertinib treatment (hazard ratio, 0.30;
95% CI, 0.23-0.41; P < 0.001; 4.4 months vs. 10.1 months). Simi-
larly, the ORR was significantly higher with osimertinib (71.1%)
compared with platinum-based therapy plus pemetrexed (31%).21
This current subgroup analysis, prespecified in the statistical analy-
sis plan of the AURA3 study, was designed to investigate the effi-
cacy and safety of osimertinib in the Japanese patients enrolled in
AURA3.
2 | MATERIALS AND METHODS
2.1 | Trial design
Patients were enrolled from 24 centers in Japan. The design of the
study has been reported in detail elsewhere.21
In the overall cohort, patients were randomized in a 2:1 ratio to
receive either osimertinib or pemetrexed plus either carboplatin or
cisplatin (platinum-pemetrexed). Investigators chose either carbo-
platin or cisplatin for each patient before randomization. Patients
were randomized centrally using an interactive voice/web response
system. Sixty-three (15%) of the 419 participants enrolled in the
original AURA3 study were recruited in Japan and were included in
the current analysis.
All patients provided written informed consent prior to screen-
ing. Patients were free to discontinue treatment or to withdraw con-
sent to participate in the study at any time. The study adhered to
the principles laid down in the Declaration of Helsinki and relevant
local and international guidelines and was approved by ethics com-
mittees or institutional review boards at all participating institutions.
The study is registered at ClinicalTrials.gov (NCT02151981).
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2.2 | Patients
Male and female patients aged ≥18 years (≥20 years in Japan) and
who provided written informed consent were included. Specific
inclusion criteria were as follows: (i) locally advanced or metastatic,
histologically or cytologically documented NSCLC not amenable to
surgery or radiotherapy; (ii) evidence of disease progression follow-
ing first-line EGFR-TKI therapy; (iii) documented EGFR mutation and
central confirmation of tumor EGFR T790M mutation from a tissue
biopsy taken after disease progression following first-line EGFR-TKI
treatment; (iv) WHO performance status of 0 or 1; (v) no more
than 1 prior line of treatment for advanced NSCLC; and (vi) no
prior neoadjuvant or adjuvant chemotherapy treatment in the
6 months preceding the first EGFR-TKI treatment. Patients with
stable asymptomatic CNS metastases (defined as not requiring cor-
ticosteroids for 4 weeks before study treatment) were eligible for
inclusion.
The exclusion criteria were as follows: (i) treatment with an
approved EGFR-TKI within 8 days of the first dose of study treat-
ment; (ii) prior treatment with osimertinib or any T790M-directed
EGFR-TKI; (iii) prior use of investigational agents or anticancer drugs
within 14 days of randomization; and (iv) inadequate bone marrow
reserve or organ function.
2.3 | Interventions
This was an open-label study. In the osimertinib group, patients
received oral osimertinib at a dose of 80 mg once daily. In the plat-
inum-pemetrexed group, patients received i.v. pemetrexed 500 mg/
m2 plus either carboplatin at an area under the plasma concentra-
tion-time curve of 5, or cisplatin 75 mg/m2 every 3 weeks for up to
6 cycles. Optional maintenance pemetrexed treatment was permitted
for patients whose disease had not progressed after 4 cycles of plat-
inum-pemetrexed.
Treatment continued until disease progression, the development
of unacceptable AEs, or a request by either the patient or the physi-
cian to discontinue treatment. In accordance with a protocol amend-
ment, patients assigned to platinum-pemetrexed could be switched
to osimertinib in the event of disease progression assessed by the
investigator and confirmed by a blinded independent central review
committee.
2.4 | Outcomes
The primary outcome measure was PFS assessed by the investigator
according to RECIST version 1.1. Analysis of PFS by a blinded inde-
pendent central review committee was carried out as a sensitivity
analysis. All patients had RECIST 1.1 assessments every 6 weeks
until objective progression. Secondary outcome measures included
overall survival, ORR, duration of response, DCR, tumor shrinkage,
and safety and tolerability. Safety assessments included clinical
chemistry, hematology and urinalysis, vital signs and physical exami-
nation, echocardiogram/multigated acquisition scan, and WHO
performance status. Adverse events were classified using the NCI’s
CTCAE version 4.0.
2.5 | Statistical analyses
A full description of the statistical analyses, including the sample size
calculation, has been reported in detail elsewhere.21 The full analysis
set included all randomized patients and was used for all efficacy
and exploratory analyses. The safety analysis set comprised all
patients who received at least 1 dose of randomized treatment. No
statistical analyses were undertaken for safety data and they were
presented as summary data. All calculations were carried out with
SAS software version 9.4 (SAS Institute, Cary, NC, USA).
3 | RESULTS
3.1 | Patients
Patients were enrolled and randomized between August 2014 and
September 2015. The tissue biopsy samples of 174 Japanese
patients were screened by central testing for EGFR T790M muta-
tions after progression, prior to study entry. Of the 111 patients
excluded for not meeting eligibility criteria, EGFR T790M mutation
was not confirmed in 97 patients. Sixty-three Japanese patients
were randomized and received treatment (osimertinib, n = 41; and
platinum-pemetrexed, n = 22). Fifteen out of 19 patients (78.9%)
who discontinued randomized treatment in the platinum-pemetrexed
arm at the data cut-off (15 April 2016) crossed over to the osimer-
tinib arm. The patient disposition in the Japanese subgroup is shown
in Figure 1.
Table 1 provides the characteristics of enrolled patients in the
overall cohort and the Japanese subgroup. Patient characteristics in
the Japanese subgroup were comparable with those in the overall
study cohort. Baseline characteristics were generally balanced across
treatment groups in the overall study cohort and in the Japanese
subgroup. In the Japanese subgroup, 63.5% of patients were female
(n = 40) and 65.1% were never-smokers (n = 41). The percentage of
patients with CNS metastases at baseline was 30.2% (n = 19) in the
Japanese subgroup (29.3% in the osimertinib group and 31.8% in the
platinum-pemetrexed group; Table 1).
At the data cut-off, the median duration of treatment was
9.95 months (range, 0.6-17.5 months) for osimertinib and
5.03 months (range, 0.7-14.0 months) for platinum-pemetrexed.
After disease progression, patients were treated with chemotherapy
(platinum doublet, monotherapy), EGFR-TKIs, immune checkpoint
inhibitors, or radiation therapy.
3.2 | Progression-free survival and tumor responses
Figure 2 shows PFS in the global cohort21 and Japanese subgroup.
PFS was longer in the osimertinib group than in the platinum-peme-
trexed group. In the Japanese subgroup, the hazard ratio was 0.27
(95% CI, 0.13-0.56), and the median PFS was 12.5 months in the
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osimertinib group and 4.3 months in the platinum-pemetrexed
group. These results were consistent with those in the global cohort.
Table 2 shows a comparison of best objective responses, the ORR,
DCR, and duration of response in the 2 treatment groups. The mean
reduction of tumor size in the target lesion after 6 weeks was 34.7%
in the osimertinib group and 18.8% in the platinum-pemetrexed
group. All 41 patients in the osimertinib group showed a reduction
of tumor size in the target lesion regardless of the best objective
response (partial response, stable disease, or progressive disease).
Among patients in the platinum-pemetrexed group, most (19/22,
86.4%) showed a reduction of tumor size in the target lesion, except
for 3 patients (3/22, 13.6%) who showed an increase of tumor size
in the target lesion (1 patient with stable disease and 2 patients with
progressive disease) (Figure S1). The findings for secondary out-
comes were broadly similar between the Japanese patients and the
overall cohort. Overall survival was not analyzed because the data
were immature at the cut-off.
3.3 | Safety
Adverse events occurred in all patients in both groups. Grade ≥3
AEs or SAEs were reported in a higher proportion of patients in the
platinum-pemetrexed group (Table 3). Adverse events that were
determined as possibly related to treatment by investigators in the
Japanese subgroup analysis (summarized in Table 4) occurred in 39
patients (95.1%) treated with osimertinib and 22 patients (100%)
treated with platinum-pemetrexed. Paronychia, diarrhea, and skin
events including dry skin, pruritus, and dermatitis acneiform were
observed in higher proportions in the osimertinib group than in the
platinum-pemetrexed group. Nausea, malaise, decreased appetite,
anemia, constipation, decreased platelet count, decreased neutrophil
count, decreased white blood cell count, increased alanine amino-
transferase, increased aspartate aminotransferase, stomatitis, fatigue,
and pyrexia were more frequent in the platinum-pemetrexed group
than in the osimertinib group.
The CTCAE grade ≥3 AEs judged as possibly related to
osimertinib included increased alanine aminotransferase, increased
aspartate aminotransferase, diarrhea, and decreased appetite.
Adverse events of CTCAE grade ≥3 were reported in 13 patients
(31.7%) treated with osimertinib and in 15 patients (68.2%) trea-
ted with platinum-pemetrexed. Grade ≥3 AEs that were deter-
mined as possibly related to treatment by investigators occurred
in 5 patients (12.2%) treated with osimertinib and 12 patients
(54.5%) treated with platinum-pemetrexed. Adverse events causally
related to treatment that led to treatment discontinuation
occurred in 3 patients (7.3%) treated with osimertinib and 2
Assessed for eligibility (n = 174)Enrollment
Excluded  (n = 111)
• Did not meet eligibility criteria (n = 108)
• Patient withdrawal (n = 3)




Allocated to osimertinib (n = 41)
• Received osimertinib (n = 41)
• Did not receive osimertinib (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 17)
• Adverse event (n = 2)
• Max chemotherapy cycles reached (n = 0)
• Objective disease progression (n = 14)
• Patient  decision (n = 0)
• Other (n = 1)
Lost to follow-up (n = 0)
Discontinued intervention (n = 19)
• Adverse event (n = 2)
• Max chemotherapy cycles reached (n = 3)
• Objective disease progression (n = 13)
•   Patient decision (n = 1)
• Other (n = 0)
Allocated to platinum–pemetrexed (n = 22)
• Received platinum–pemetrexed (n = 22)
• Did not receive osimertinib (n = 0)
Analyzed (n = 41)
• Excluded from analysis (n = 0)
Analyzed (n = 22)
• Excluded from analysis (n = 0)
F IGURE 1 Patient disposition in the Japanese subgroup of patients with EGFR T790M mutation-positive advanced non-small-cell lung
cancer treated with osimertinib or platinum-pemetrexed therapy. Patients in the platinum-pemetrexed group were counted only if they
discontinued all platinum-pemetrexed treatment. If a patient discontinued platinum-pemetrexed treatments at different times during the trial,
they were counted under the last recorded reason for discontinuation of platinum-pemetrexed. If a patient discontinued platinum-pemetrexed
treatments at the same time, the patient was counted under a single reason using the following order: adverse event, objective disease
progression, severe protocol non-compliance, lost to follow-up, patient decision, maximum cycle of platinum-pemetrexed reached, or other
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patients (9.1%) treated with platinum-pemetrexed. In the osimer-
tinib group, these were ILD-like AEs (1 patient with grade 1 pneu-
monitis and 2 patients with grade 2 ILD). Grade 2 events of QT
prolongation were reported in 1 patient (2.4%) treated with
osimertinib and 1 patient (4.5%) treated with platinum-pemetrexed
(Table 4).
Serious AEs were less common in the osimertinib group than the
platinum-pemetrexed group (5 patients [12.2%] vs. 6 patients
[27.3%], respectively). One Japanese patient, whose events were
considered possibly related to study treatment by the investigator,
developed interstitial pneumonitis almost 7 months after starting
treatment, and treatment was discontinued. Nine days later, pneu-
mothorax was reported but the patient subsequently recovered. In
total, 4 (9.8%) patients in the osimertinib group and 5 (22.7%)
patients in the platinum-pemetrexed group died, including those who
died during the crossover period or after the follow-up period. All 9
deaths, including all 4 in the osimertinib group, were considered
related to the disease under investigation. No fatal SAE was
reported in the Japanese subgroup.
4 | DISCUSSION
The objective of the current study was to evaluate the safety and
efficacy of osimertinib in the 63 Japanese patients enrolled in
AURA3. This was a randomized, open-label, phase III clinical trial of
NSCLC patients with the EGFR T790M mutation whose disease pro-
gressed after first-line EGFR-TKI treatment.
Our findings in the Japanese subgroup are consistent with those
for the overall study cohort.21 Clinically relevant improvements were
TABLE 1 Demographic characteristics in the overall study cohort and Japanese subgroup of patients with EGFR T790M mutation-positive
advanced non-small-cell lung cancer treated with osimertinib or platinum-pemetrexed
Characteristic
Osimertinib Platinum-pemetrexed
All patients21 (n = 279) Japanese patients (n = 41) All patients21 (n = 140) Japanese patients (n = 22)
Sex, %
Male 38.4 36.6 30.7 36.4
Female 61.6 63.4 69.3 63.6
Age, years, median (range) 62.0 (25-85) 69 (25-85) 63.0 (20-90) 67 (33-90)
Race, %




Never 67.7 68.3 67.1 59.1
Current 5.0 14.6 5.7 13.6
Former 27.2 17.1 27.1 27.3
CNS metastasesb, % 33.3 29.3 36.4 31.8
EGFR mutationsc, %
T790Md 98.6 97.6 98.6 100.0
Exdel19 68.5 56.1 62.1 72.7
L858R 29.7 39.0 32.1 27.3
Othere 2.2 4.8 3.5 0.0
Number of previous anticancer regimens, %
1 96.4 95.1 95.7 100.0
2 3.2 4.9 4.3 0.0
3 0.4f 0.0 0.0 0.0
Exdel19, exon 19 deletion; L858R, Leu858Arg mutation.
aIncluding Black or African American and American Indian or Alaskan native.
bCentral nervous system (CNS) metastases determined programmatically from baseline date of CNS lesion site, medical history and/or surgery, and/or
radiotherapy.
cEGFR mutation identified by Cobas EGFR mutation test (by biopsy taken after confirmed progression on most recent treatment regimen).
dSix patients without centrally confirmed Thr790Met (T790M) mutation-positive status documented in the trial database/3 patients subsequently con-
firmed to be tumor T790M mutation-positive. In the Japanese subgroup, 1 patient in the osimertinib group was reported as having missing results, but
was T790M mutation-positive (100% T790M positive, n = 63): the patient had a T790M positive result recorded under the patient’s previous study
code, which was missing from the database by error.
eIncludes G719X, S768I, and exon 20 insertion.
fOne patient had 3 previous anticancer regimens.
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observed in PFS and tumor responses in the osimertinib group
compared with the platinum-pemetrexed group of the Japanese
subgroup (hazard ratio, 0.27; 95% CI, 0.13-0.56). The median PFS
was 12.5 months in the osimertinib group and 4.3 months in the
platinum-pemetrexed group.
Our results were similar to a previous Japanese phase III study in
patients with advanced EGFR-mutated NSCLC who were na€ıve to
any EGFR-TKIs and were randomized to treatment with another
EGFR-TKI treatment, gefitinib, or chemotherapy, although the target
patients were TKI-pretreated EGFR T790M mutation-positive in this
AURA3 study,2 which reported a significantly longer PFS with gefi-
tinib than chemotherapy (10.4 months vs. 5.5 months, respectively;
hazard ratio for PFS with gefitinib, 0.36; 95% CI, 0.25-0.51;
P < 0.001). This indicated that the use of osimertinib in patients har-
boring the EGFR T790M mutation after disease progression by prior
EGFR-TKI therapy is supported even in the Japanese population.
Notably, among 174 Japanese and 1036 overall patients screened,
63 (36.2%) and 413 (39.9%) patients, respectively, were enrolled in
the study with T790M mutation-positive status.21 Thus, the propor-
tion of patients with documented EGFR T790M mutation between
the Japanese and global cohorts was broadly similar.
Treatment options for NSCLC patients with EGFR mutations who
experienced disease progression after EGFR-TKI therapy are limited.
The LUX-Lung 1 and LUX-Lung 4 trials evaluated the efficacy of afa-
tinib in NSCLC patients after failure with erlotinib or gefitinib in a
global study cohort and Japanese patients, respectively.11,12 In these
studies, only a small portion of the patients possessed EGFR T790M
mutations. The PFS ranged between 3 and 4 months, ORR ranged
between 7% and 8%, and no clinically significant response was
found.
The IMPRESS trial evaluated the efficacy and safety of continu-
ing gefitinib combined with chemotherapy vs chemotherapy alone
in patients with EGFR mutation-positive advanced NSCLC with
acquired resistance to first-line gefitinib. The median PFS and ORR
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F IGURE 2 Progression-free survival (PFS) using investigator
assessment in all patients21 (A) and Japanese patients (B) enrolled
with EGFR T790M mutation-positive advanced non-small-cell lung
cancer treated with either osimertinib or platinum-pemetrexed
therapy. A, In all patients, the median PFS was 10.1 mo (95%
confidence interval [CI], 8.3-12.3) in the osimertinib group and 4.4
(95% CI, 4.2-5.6) in the platinum-pemetrexed group (hazard ratio,
0.30; 95% CI, 0.23-0.41; P < 0.001). B, In the Japanese patients, the
median PFS was 12.5 mo (95% CI, 6.9-not calculated) in the
osimertinib group and 4.3 (95% CI, 4.0-6.7) in the platinum-
pemetrexed group (hazard ratio, 0.27; 95% CI, 0.13-0.56)
TABLE 2 Tumor response in the Japanese subgroup of patients
with EGFR T790M mutation-positive advanced non-small-cell lung






Best objective response, n (%)
Complete response 0 (0.0) 0 (0.0)
Partial response 29 (70.7) 8 (36.4)
Non-response (total) 12 (29.3) 14 (63.6)
Stable disease ≥6 wk 10 (24.4) 11 (50.0)
Progression 2 (4.9) 3 (13.6)
RECIST progression 2 (4.9) 2 (9.1)
Death 0 (0.0) 1 (4.5)
Objective response rate (%)a 70.7 36.4




11.1 (6.5-NC) 4.1 (1.5-7.1)
Patients remaining in
response, n (%)
>3 mo 26 (89.7) 5 (62.5)
>6 mo 19 (65.5) 2 (25.0)
>9 mo 11 (37.9) 1 (12.5)
>12 mo 2 (6.9) 1 (12.5)
NC, not calculated.
aOdds ratio, 4.23 (95% confidence interval [CI], 1.45-13.23).
bOdds ratio, 3.08 (95% CI, 0.47-24.89).
cFrom onset of response.
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IMPRESS trial were 5.4 months (95% CI, 4.6-5.5) and 34%, respec-
tively.22 Thus, the median PFS and ORR in the AURA3 trial is con-
sidered to be broadly similar to the historical data. However, these
comparisons should be interpreted with caution as there is no
specific study of platinum doublet chemotherapy in patients with
T790M mutation-positive NSCLC who have progressed on prior
EGFR-TKI therapy, and the trials compared here are heteroge-
neous.
A retrospective analysis of 24 patients treated with EGFR-TKI
rechallenge in combination with bevacizumab showed a higher DCR
(88%) and a slightly longer PFS (4.1 months) than have previously
been published for similar patients treated with EGFR-TKI rechal-
lenge alone. Furthermore, both the DCR and PFS in this study were
higher in EGFR T790M mutation-negative patients compared with
those in EGFR T790M mutation-positive patients (DCR 88% vs. 86%
[P = 1.00] and PFS 4.1 vs. 3.3 months [P = 0.048], respectively).23
Although the present study showed clinically meaningful improve-
ment in PFS in the osimertinib group vs the platinum-pemetrexed
group, further study is warranted to determine whether combination
treatment with anti-vascular endothelial growth factor therapy would
provide any additional benefit, particularly in EGFR T790M mutation-
positive patients.
In the current study, there were small numerical differences in
AEs in the osimertinib group compared with the overall study cohort
(22%).21 However, the safety profile of osimertinib in the Japanese
patients was broadly similar to the overall cohort and no new safety
signals were presently identified. Three Japanese patients in the
osimertinib group experienced 3 ILD-related AEs (CTCAE grades 1
and 2), and all 3 patients recovered. There was no increase in ILD
severity in the Japanese subgroup compared with the overall study
cohort.
This study has some limitations, including its open-label nature.21
Given that this was a subgroup analysis, the number of patients is
relatively small, meaning results should be interpreted with some
caution.
In conclusion, the results of this study suggest that osimertinib is
effective as a standard regimen in Japanese NSCLC patients carrying
the EGFR T790M mutation with disease progression after EGFR-TKI
therapy. Osimertinib was relatively well tolerated, with low inci-
dences of causally related AEs classified as CTCAE grade ≥3 or SAEs.
The findings in this subgroup of Japanese patients were consistent
with those observed in the overall study cohort.
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TABLE 3 Rates of adverse events (AEs) in the overall study cohort and Japanese subgroup of patients with EGFR T790M mutation-positive









patients (n = 22)
AE, anya, n (%)
Any AE 273 (97.8) 41 (100.0) 135 (99.3) 22 (100.0)
Any AE grade ≥3 63 (22.6) 13 (31.7) 64 (47.1) 15 (68.2)
Any AE leading to death 4 (1.4) 0 (0.0) 1 (0.7) 0 (0.0)
Any serious AE 50 (17.9) 5 (12.2) 35 (25.7) 6 (27.3)
Any AE leading to discontinuation 19 (6.8) 3 (7.3) 14 (10.3) 2 (9.1)
AE, possibly causally related, n (%)
Any AE 231 (82.8) 39 (95.1) 121 (89.0) 22 (100)
Any AE grade ≥3 16 (5.7) 5 (12.2) 46 (33.8) 12 (54.5)
Any AE leading to death 1 (0.4) 0 (0.0) 1 (0.7) 0 (0.0)
Any serious AE 8 (2.9) 1 (2.4) 17 (12.5) 5 (22.7)
Any AE leading to discontinuation 10 (3.6) 3 (7.3) 12 (8.8) 2 (9.1)
Safety analysis set (all patients who received at least 1 dose of the study drug and for whom post-dose data were available). Adverse events were
assessed by the investigator, and include those with an onset date on or after the date of the first dose and up to and including 28 days following the
date of the last dose of study medication.
aPatients with multiple events in the same category were only counted once in that category. Those with events in more than 1 category were counted
once in each category.
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TABLE 4 Possibly causally related adverse events (AEs) in the Japanese subgroup of patients with EGFR T790M mutation-positive advanced
non-small-cell lung cancer treated with osimertinib or platinum-pemetrexed
Osimertinib (n = 41) Platinum-pemetrexed (n = 22)
Any grade Grade ≥3 Any grade Grade ≥3
All AEs >15%, n (%)
Any AE 39 (95.1) 5 (12.2) 22 (100) 12 (54.5)
Paronychia 18 (43.9) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhea 14 (34.1) 1 (2.4) 2 (9.1) 0 (0.0)
Dry skin 8 (19.5) 0 (0.0) 1 (4.5) 0 (0.0)
Stomatitis 7 (17.1) 0 (0.0) 7 (31.8) 0 (0.0)
Pruritus 7 (17.1) 0 (0.0) 1 (4.5) 0 (0.0)
Dermatitis acneiform 6 (14.6) 0 (0.0) 0 (0.0) 0 (0.0)
Nausea 2 (4.9) 0 (0.0) 14 (63.6) 0 (0.0)
Malaise 0 (0.0) 0 (0.0) 12 (54.5) 0 (0.0)
Decreased appetite 2 (4.9) 1 (2.4) 11 (50.0) 4 (18.2)
Anemia 2 (4.9) 0 (0.0) 10 (45.5) 4 (18.2)
Constipation 1 (2.4) 0 (0.0) 10 (45.5) 0 (0.0)
Platelet count decreased 4 (9.8) 0 (0.0) 7 (31.8) 3 (13.6)
Neutrophil count decreased 3 (7.3) 0 (0.0) 7 (31.8) 4 (18.2)
White blood cell count decreased 5 (12.2) 0 (0.0) 5 (22.7) 2 (9.1)
Alanine aminotransferase increased 5 (12.2) 2 (4.9) 4 (18.2) 0 (0.0)
Fatigue 1 (2.4) 0 (0.0) 4 (18.2) 0 (0.0)
Aspartate aminotransferase increased 5 (12.2) 2 (4.9) 4 (18.2) 0 (0.0)
Pyrexia 0 (0.0) 0 (0.0) 4 (18.2) 0 (0.0)
Select adverse events <15%, n (%)
Interstitial lung diseasea 3 (7.3) 0 (0.0) 0 (0.0) 0 (0.0)
QT prolongation 1 (2.4) 0 (0.0) 1 (4.5) 0 (0.0)
Safety analysis set (all patients who received at least 1 dose of the study drug and for whom post-dose data were available). Adverse events were
assessed by the investigator, and include those with an onset date on or after the date of the first dose and up to and including 28 days following dis-
continuation of randomized treatment or the day before first administration of cross-over treatment if within 28 days. Some patients had more than 1
AE.
aGrouped term: if a patient had multiple preferred term level events within a specific grouped term AE, then the maximum grade of CTCAE across those
events was counted.
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